guidebook. - Fanconi Anemia Research Fund

More documents

Recommendations

Info

Index 373 anticonvulsant therapy, risks of, 158 anus, anal atresia, 46, 77, 79; ectopic, 77, 342; imperforate, 35, 38, 353 aperistalsis, 213, 334 appetite, 140; glucocorticoids, effect on, 158; stimulants, 85-86; supplemental feeds, 83-84 arm lengthening, see forearm lengthening arthritis, 70, 72 asceptic necrosis of bone or joints, see avascular necrosis aspartate transaminase (AST), 87, 89, 90, 233, 335, 365 asthma, 204 autosomal recessive inheritance, 33, 275-277, 335, see also genetic counseling avascular necrosis, 60, 214, 216, 227, 336 azoospermic, 268 bacteremia, 229 beta cell dysfunction, 146-147, 159 betel nut chewing, 251 biliary, bilirubin, 88, 90-91, 186, 210, 233, 336; hyperbilirubinemia, 213, 351 bladder abnormalities, 36, 202, 204, 210, 212 bleeding, 72, 91; esophageal, 84; from duodenal intubation, 80; from fish oil (omega-3 fatty acid), 94; from gastroesophageal reflux, 78; from ginkgo, 204; from hepatic adenoma, 90; hemorrhagic cystitis, 212; menstrual breakthrough, 124, 153; mucosal, 73; oral, 253; risk from drugs such as aspirin or ibuprofen, 73; side effect of cyclosporine A/tacrolimus, 214; uterine or menstrual, 123-124 blind loop syndrome, 78, 337 blood counts, 340; post-transplant, 193-194, 226, 232; to monitor bone marrow failure, 52, 54-56, 63, 65, 188 body mass index, 82-83, 87, 122, 139, 228 bone age, 137-138, 155, 232 bone marrow, 337; aplasia, 178; aspiration, 74, 210, 337; biopsy, 50, 53, 61, 74, 188, 210, 232, 337; blast count, 184, 331, 337; cellularity, 50, 53, 61, 217; clinical monitoring and management of failure, 50, 53-56, 62-65; clonal abnormalities, see clones, cytogenetic clonal abnormalities; dysfunction, 49, 188; dysplasia, 50-51, 54, 184-185, 187, see also myelodyplasia; examination, 53, 74; onset of anemia, 66; severity of failure, 53; suppression of, secondary to H2-antagonists, 81; suppression of, secondary to infection, 50; transplant, see transplant;
374 <strong>Fanconi</strong> <strong>Anemia</strong>: Guidelines for Diagnosis and Management treatment options for failure, 56-61 bone mineral density, see osteopenia, osteoporosis bowel, antegrade continence enema (ACE) procedures, 79; constipation, 73, 79, 80; encopresis, 79-80, 342; fecal incontinence, 79; malabsorption, 80, 83, 92, 140, 213; obstruction, 81; small bowel overgrowth, 79, 80 BRCA1, 284 breast cancer susceptibility genes, 282 breast pain, 283 bronchitis, 204 BUN (blood urea nitrogen test), 233, 337 café au lait spots, 34, 38, 44, 98, 204, 338 cancer, early age of onset, 276, 281, 283; family history of, 224, 276; primary tumor, more than one, 276; risk in non-transplanted FA patients, 36; risk of, 37-38, 144, 217, 251, 268, 281, 284; secondary, 180, 190, 252-253; surveillance for, 33, 122, 126, 229-230, 255-257, 262, 280-281 cancer, types of, acute lymphocytic (lymphoid) leukemia, 36, 50, 331; acute myelogenous leukemia (AML), 33, 35-38, 43, 49-52, 57, 64-65, 144-145, 180-181, 183-185, 190, 205, 331, 355; adenocarcinoma, 60, 332; anal, 39, 122, 125; astrocytoma, 280; bladder, 36; brain, 36, 39, 210, 230, 280; breast, 36, 39-40, 126, 129, 199, 230, 268, 276, 282-285; breast, male, 276, 282-285; cervical, 36, 38, 122-123, 125, 204, 267; chronic myelomonocytic leukemia, 36; colon, 36, 78; dermatofibroma, 36, 341; esophageal, 36-37; gastrointestinal, 268; genitourinary, 190, 194, 204; gynecological, 37, 122-123, 125-126, 144, 230; head and neck squamous cell carcinoma, see head and neck squamous cell carcinoma; human papillomavirus (HPV)- associated, 123, 126, 217, 230, 251, 253-254, 267, 350; kidney, see cancer, renal; liver (hepatocellular), 36-39, 58, 60, 90, 203, 349; lung, 36; lymphoma, 36, 356; medulloblastoma, 46, 230, 280, 357; melanoma, 204, 282; neuroblastoma, 36, 359; osteosarcoma, 36, 360; ovarian, 276, 282-283; pancreatic, 282; prostate, 276, 282-283; renal, 36, 210; retinoblastoma, 36, 364; skin, 230; stomach, 36; vaginal, 125; vulvar, 36, 39, 122, 125-126, 204, 267; Wilms tumor, 36, 39, 46, 230, 280, 369 cardiac, arrhythmias, 68, 72; cardiac iron toxicity, 67-70, 72, 194; cardiac siderosis, 67; cardiovascular disease, 129-130, 228, 268; function, 186, 210; heart muscle injury, 212; tachycardia, 66; toxicity, late complication of transplant, 194; VACTERL
Page 1 and 2:
Fanconi Anemia: Guidelines for Diag
Page 3 and 4:
We are deeply grateful to the follo
Page 5 and 6:
iv Fanconi Anemia: Guidelines for D
Page 7 and 8:
vi Fanconi Anemia: Guidelines for D
Page 9 and 10:
8 Fanconi Anemia: Guidelines for Di
Page 11 and 12:
10 Fanconi Anemia: Guidelines for D
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Chapter 4 Gastrointestinal, Hepatic
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
100 Fanconi Anemia: Guidelines for
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Chapter 7 Endocrine Disorders in Fa
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Chapter 9 Matched Sibling Donor Hem
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Chapter 12 Novel Treatment Options
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Chapter 13 Head and Neck Squamous C
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Chapter 14 The Adult Fanconi Anemia
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324: 322 Fanconi Anemia: Guidelines for
Page 373: 372 Fanconi Anemia: Guidelines for
show all

guidebook. - Fanconi Anemia Research Fund

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?